Myocardial Infarction, Pulmonary Embolism, and Deep Vein Thrombosis Following Testosterone Cypionate Use: A Pharmacovigilance Study
Based on the current FAERS data, testosterone cypionate does not appear to increase the risk of major cardiovascular events more than expected. Still, serious outcomes can and do happen, especially in patients with more complex medical histories. These results highlight the importance of evaluating each patient's individual risk and show why post-marketing surveillance remains such an important tool for tracking drug safety in real-world clinical settings.
Authors
- Deepak K. Gupta (ORCID: https://orcid.org/0000-0003-2191-3485)
- Augustine T. Nkembo (ORCID: https://orcid.org/0000-0002-2191-4907)
- Vijaykumar Sutariya (ORCID: https://orcid.org/0000-0001-8998-2298)
- Priyanka Sharma (ORCID: https://orcid.org/0000-0002-1520-1126)
- Abhishek Kandukuru
- Aishwarya Kandukuru
- Sheeba Varghese Gupta
Institutions
- Lake Erie College of Osteopathic Medicine (US)
- University of South Florida (US)
- University of Florida (US)
Publication Details
- Journal
- Current Drug Safety
- Published
- 2026-01-05
- DOI
- https://doi.org/10.2174/0115748863409028251030045518
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00